CARB-X teams up with HelixBind to support the development of a test to diagnose life-threatening bloodstream infections linked to sepsis

CARB-X teams up with HelixBind to support the development of a test to diagnose life-threatening bloodstream infections linked to sepsis

Helixbind’s Rapid/BSI Diagnostic Test Would Enable Doctors to Diagnose and Treat Deadly Bacterial Infections More Quickly and Effectively Than is Possible With Today’s Diagnostic Tools

(BOSTON: March 15, 2018) – CARB-X is awarding HelixBind of Marlborough, MA, up to $1 million, with the possibility of up to $1 million more based on achievement of project milestones, to support the development of the company’s RaPID/BSI diagnostic test for invasive bloodstream infections. The test aims to identify infections directly from patient whole-blood and provide resistance information, giving doctors vital information they need to treat patients successfully.

“HelixBind’s diagnostic project is an exciting addition to the Powered by CARB-X portfolio, building the number of diagnostics and enhancing the portfolio’s diversity. The ability to identify drug-resistant bacterial infections in a timely manner will enable doctors to treat patients more effectively and save lives,” said Kevin Outterson, Executive Director of CARB-X. “The world urgently needs new diagnostics, antibiotics, vaccines and other products to protect us from current and emerging drug-resistant bacteria. All the projects in the Powered by CARB-X are in the early stages of development, but if successful, they offer great potential in the fight against life-threatening drug-resistant bacteria.”

“We believe RaPID will enable clinicians to place patients on targeted antimicrobial days sooner, leading to better outcomes, reduced time in the hospital, and improved antibiotic stewardship,” said Alon Singer, PhD, Founder and CEO of HelixBind.

Rapid accurate diagnosis means faster targeted treatment

CARB-X funding will support development and testing of the first assay to be implemented on HelixBind’s diagnostic platform. RaPID/BSI provides species level pathogen identification across a broad test menu directly from a whole-blood specimen, without the need for cultures. Current diagnostic techniques rely on blood cultures in laboratories, which can take days and may miss infections. RaPID/BSI aims to produce an accurate diagnostic within hours, taking the guesswork out of treatment decisions in the first critical few hours and days of illness.

Sepsis, a leading cause of death worldwide, is the body’s overwhelming immune response to a bloodstream infection. Infection-fighting chemicals released into the blood trigger widespread inflammation which can lead to tissue and organ damage and can be deadly. According to the US Centre for Disease Control and Prevention (CDC), an estimated 250,000 people die each year from sepsis. Faster diagnosis and treatment could potentially lower mortality rates.

CARB-X portfolio expanding

The CARB-X portfolio is the world’s largest and most scientifically diverse portfolio of early development antibacterial projects with 27 projects including antibiotics and other therapeutics, vaccines and diagnostics to respond to the threat of drug-resistant bacteria. CARB-X, which stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, funds projects in 6 countries and is working to expand its pipeline with the best science from around the world.

Since it was established in 2016, CARB-X has announced awards totaling $69.2 million, plus an additional $86.1 million if project milestones are met, to accelerate the development of antibiotics and other products. These funds are in addition to investments made by the companies themselves.

New antibiotics, diagnostics and other products are needed urgently to treat bacteria that are becoming increasingly resistant to existing antibiotics. According to the World Health Organization (WHO), an estimated 700,000 people die each year worldwide from bacterial infections. According to the CDC, in the United States alone, an estimated 23,000 people die each year from drug-resistant bacterial infections.

Partnership to drive antibacterial innovation

CARB-X is a partnership between the UK charity Wellcome Trust and the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

CARB-X funding is part of a commitment of up to $455m by the US government and Wellcome Trust from 2016-2021. CARB-X is seeking global support from other governments, industry and civil society to expand its ability to fund the best science projects around the world to support new life-saving products that are urgently needed.

CARB-X identifies and funds promising early development research to treat the most serious bacteria. The goal is to support projects through the early phases so that they will attract additional private or public support for clinical development. To be considered for CARB-X support, projects must target antibiotic-resistant bacteria on the Serious or Urgent Threat List prepared by the CDC or on the Priority Pathogens list published by the WHO. Responsible use of existing antibiotics and equitable access, particularly in low-income countries where need is greatest, is also vital to addressing the global health problem. Both are a condition of CARB-X funding.

This news release is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by an award from Wellcome Trust, as administrated by CARB-X. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the HHS Administration for Strategic Preparedness and Response, the National Institutes of Health or Wellcome Trust.

For information:

CARB-X: Jennifer Robinson

David Steinmiller

About CARB-X

CARB-X is the world’s largest public-private partnership devoted solely to accelerating early development antibacterial R&D. Funded by ASPR/BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X is investing up to $455 million from 2016-2021 to support innovative antibiotics and other therapeutics, vaccines, rapid diagnostics and devices to treat drug-resistant bacterial infections. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI).

About HelixBind Inc.

HelixBind is a privately held company devoted to improving the diagnosis and management of invasive infections. Its proprietary RaPID platform provides culture-free characterization of bacterial and fungal pathogens and their resistance mechanisms direct from patient specimens, enabling clinicians to quickly diagnosis and monitor infection progression to ensure prompt and appropriate care. For more information, visit


RaPID/BSI, the first test to be implemented on HelixBind’s RaPID platform, targets bloodstream infections (BSIs). Sepsis, the body’s severe immune response to a BSI, is a leading cause of death and major driver of healthcare costs worldwide. Effective management requires timely and accurate diagnosis, but current practices are limited and often take days to provide the needed information. RaPID/BSI will provide the information clinicians need sooner and with more certainty promising improved patient care, reduced hospitalizations stays, and improved antimicrobial stewardship.

About Wellcome Trust

Wellcome exists to improve health for everyone by helping great ideas to thrive. We’re a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate. The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

About HHS, ASPR and NIH

HHS is the principal federal agency for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves.

ASPR’s mission is to save lives and protect Americans from 21st century health security threats. ASPR leads the federal public health and medical preparedness and response to disasters and other emergencies, on behalf of the Secretary of HHS. Within ASPR, BARDA provides a comprehensive integrated portfolio approach to the advanced research and development, innovation, acquisition, and manufacturing of vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health emergency threats. These threats include chemical, biological, radiological, and nuclear threat agents, pandemic influenza, and emerging infectious diseases.

NIAID is one of the 27 Centers and Institutes of the National Institutes of Health (NIH) a component of the U.S. Department of Health and Human Services. NIH is the nation’s medical research agency, and is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. NIAID conducts and supports research – at NIH, throughout the United States, and worldwide – to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. For more information about NIH and its programs, visit News releases, fact sheets and other NIAID-related materials are available on the NIAID website:

About Boston University

A leading research university with over 33,000 undergraduate and graduate students from more than 130 countries, nearly 10,000 faculty and staff, 17 schools and colleges, and 250 fields of study. Boston University is consistently ranked among the world’s best research universities and is a member of the American Association of Universities. For further information, see or contact Ann Comer-Woods

About the Broad Institute of MIT and Harvard

Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods, and data openly to the entire scientific community. Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff, and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, In support of CARB-X, the Broad Institute created the Collaborative Hub for Early Antibiotic Discovery (CHEAD), which serves an interdisciplinary center that partners with academic investigators engaged in antibiotic development and/or resistance research to accelerate their early-stage, small molecule therapeutics toward Investigational New Drug (IND) application.

About MassBio

MassBio is a not-for-profit organization founded in 1985 that represents and provides services and support for the world’s leading life sciences supercluster.

MassBio is committed to advancing Massachusetts’ leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives.

Representing 1000+ biotechnology companies, academic institutions, disease foundations and other organizations involved in life sciences and healthcare, MassBio leverages its unparalleled network of innovative companies and industry thought leaders to advance policy and promote education, while providing member programs, events, industry information, and services. Learn more at MassBio

About the California Life Sciences Institute (CLSI)

The mission of the California Life Sciences Institute (CLSI) is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. Located in the birthplace of biotechnology, CLSI strives to ensure that the economic and intellectual power of the region’s life sciences industry and its employees remains strong. By maintaining its focus on entrepreneurship, education and career development programs, CLSI supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem. As a non-profit 501(c)(3), CLSI’s objectives are met through collaborations, partnerships, and the generosity of individuals, sponsors and foundations. CLSI is a member of the CARB-X consortium, serving as an accelerator. Learn more at

About RTI International

RTI International is an independent, nonprofit research institute dedicated to improving the human condition. Clients rely on us to answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development. We believe in the promise of science, and we are inspired every day to deliver on that promise for the good of people, communities, and businesses around the world. For more information, visit